Balchem Q3 net sales up 4.3% to $239.9M; record adjusted EBITDA $64.4M, up 7.6% YoY

BALCHEM CORP

2024-Q3 EPS reported $2.90 revenue$713,680,000

GAAP EPS $1.03 versus $0.90 prior year; adjusted EPS record $1.13 versus $1.04.
Human Nutrition & Health and Specialty Products segments drove strong sales and earnings growth.
Cash from operations $51.3M; free cash flow $42.2M; repaid $39.6M revolving debt, net debt $153.3M (0.6x leverage).
Launched K2Vital Delta Fermented, VitaCholine Pro-Flo, and AminoShure-XL during the quarter.
Year-to-date 2024 net earnings $94.9M vs $81.9M; net sales $713.7M vs $693.7M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.